For the first time, the US Food and Drug Administration (FDA) has approved a medication to treat two kinds of advanced cancers, if standard therapies fail. The cancers are renal cell carcinoma (RCC; kidney cancer) and gastro-intestinal stromal tumours (GIST, a rare form of gastrointestinal cancer). SUTENT® has been developed on the basis of discoveries of Max Planck scientists. Cancer researcher Professor Axel Ullrich, a director at the Max Planck Institute of Biochemistry in Martinsried, Germany, already showed at the beginning of the 1990s that blocking blood vessel development in a tumour slows down its growth, and shrinks its tissue. This fundamental principle led to the development of SUTENT®, whose active ingredient is Sunitinib. SUTENT® was recently approved for clinical use in the United States, and it is expected to be brought onto the German market this year.